ResMed Inc
(STU:RME)
€
232.3
-1.9 (-0.81%)
Market Cap: 34.52 Bil
Enterprise Value: 34.92 Bil
PE Ratio: 32.70
PB Ratio: 6.98
GF Score: 98/100 Resmed Inc at Morgan Stanley Healthcare Conference Transcript
Sep 09, 2019 / 06:50PM GMT
Release Date Price:
€127.8
(+1.27%)
Sean M. Laaman
Morgan Stanley, Research Division - Australian Healthcare Analyst
Pleasure today to be joined by David Pendarvis, SVP, from ResMed. So thank you for your time today, David.
David B. Pendarvis
ResMed Inc. - Chief Administrative Officer, Global General Counsel & Secretary
Thanks for having us, Sean.
Questions & Answers
Sean M. Laaman
Morgan Stanley, Research Division - Australian Healthcare Analyst
Welcome. Maybe start by talking about the company's 2025 strategy and educate us what that means and where you're heading?
David B. Pendarvis
ResMed Inc. - Chief Administrative Officer, Global General Counsel & Secretary
Sure. So ResMed is on a long-term journey, and we've recently solidified in on our 2025 strategy, which is trying to look at least the next 5 years out, but I think the thing I would highlight for ResMed is if you believe ResMed is on the right track and that it's -- in order to believe it's a good investment, you really have
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot